Scientific publications

In the last 10 years Syreon researchers have published more than 200 scientific papers especially in the field of health economics, health policy, health technology assessment, epidemiology and public health in prestigious scientific journals. In addition to peer-reviewed articles, our colleagues edited several books, coauthored several book chapters and white papers and contributed to major international conferences.

2020

Almási T., Abul-Mad E., George M., Arnaiz F., Elezbawy B., Nagy B., Kaló Z. Supporting role of non-governmental health insurance schemes in the implementation of universal health coverage in developing countries. Journal of Health Policy & Outcomes Research (2020) DOI:10.7365/JHPOR.2020.1.4 Link

Bogos, K., Kiss, Z., Gálffy, G., Tamási, L., Ostoros, G., Müller, V., Urbán, L., Bittner, N., Sárosi, V., Vastag, A., Polányi, Z., Nagy-Erdei, Z., Vokó, Z., Nagy, B., Horváth, K., Rokszin, G., Abonyi-Tóth, Z., Barcza, Z., & Moldvay, J. (2020). Lung Cancer in Hungary. Journal of Thoracic Oncology, 15(5), 692-699. doi:10.1016/j.jtho.2019.11.001 Link

Csanádi, M., Ágh, T., Farkas-Ráduly, S., Gros, B., Tapprich, C., Trudeau, J. J., Lipton, J. H., & Mattsson, J. (2020) Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review. Expert Review of Hematology. 2020 Sep 16:1-12. doi: 10.1080/17474086.2020.1818065 Link

Csanádi M, Gini A, Koning H, Széles G, Pitter JG, Oroszi B, Pataki P, Fadgyas-Freyler P, Korponai G, Vokó Z, Lansdorp-Vogelaar I. Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary. J Med Screen. 2020 Nov 5:969141320968598. Link

Czypionka, T., Kraus, M., Reiss, M., Baltaxe, E., Roca, J., Ruths, S., Stokes, J., Struckmann, V., Haček, R. T., Zemplényi, A., Hoedemakers, M., & Rutten-van Mölken, M. (2020). The patient at the centre: evidence from 17 European integrated care programmes for persons with complex needs. BMC Health Services Research, 20(1), 1102. doi:10.1186/s12913-020-05917-9 Link

Fasseeh AN, Karam R, Jameleddine M, George M, Kristensen FB, Al-Rabayah A, Alsaggabi A, El Rabbat M, Alowayesh M, Chamova J, Ismail A. (2020). Implementation of Health Technology Assessment in the Middle East and North Africa: Comparison Between the Current and Preferred Status. Frontiers in Pharmacology, 11, 15. doi: 10.3389/fphar.2020.00015 Link

Grigore, B., Ciani, O., Dams, F., Federici, C., de Groot, S., Möllenkamp, M., Rabbe, S., Shatrov, K., Zemplenyi, A., & Taylor, R. S. (2020). Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines. PharmacoEconomics. doi:10.1007/s40273-020-00935-1 Link

Haluzík, M., Flekač, M., Lengyel, C., Taybani, Z., Guja, C., Mihai, B.-M., Cerghizan, A., Martinka, E., Kovacs, G., & Kempler, P. (2020). Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective. Diabetes Therapy, 11(4), 1029-1043. doi:10.1007/s13300-020-00777-2 Link

Inotai, A., Tomek, D., Niewada, M., Lorenzovici, L., Kolek, M., Weber, J., Kurrat, A., Kiss, E., & Kalo, Z. (2020). Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries. Front. Pharmacol. 11: 845. doi: 10.3389/fphar. Link

Jakab I, Németh B, Elezbawy B, Karadayı MA, Tozan H, Aydın S, Shen J, Kaló Z. (2020). Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper-Middle-Income Countries-A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses. Frontiers in Pharmacology, 11, 1203. doi: 10.3389/fphar.2020.01203 Link

Kaló, Z., Zemplényi, A., Rutten-Van Molken, M., Looman, W., Huić, M., & Tandara, R. (2020). Development of transferability guidance for integrated care models with special focus on Central and Eastern European countries. Croatian Medical Journal, 61(3), 252. doi: 10.3325/cmj.2020.61.252 Link

Kovács, G., Devercelli, G., Zelei, T., Hirji, I., Vokó, Z., & Keown, P. A. (2020). Association between transplant glomerulopathy and graft outcomes following kidney transplantation: A meta-analysis. PLOS ONE, 15(4), e0231646. doi:10.1371/journal.pone.0231646 Link

Merkely, B., Szabó, A. J., Kosztin, A., Berényi, E., Sebestyén, A., Lengyel, C., Merkely, G., Karády, J., Várkonyi, I., Papp, C., Miseta, A., Betlehem, J., Burián, K., Csóka, I., Vásárhelyi, B., Ludwig, E., Prinz, G., Sinkó, J., Hankó, B., Varga, P., Fülöp, G., Mag, K., & Vokó, Z. (2020). Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. GeroScience, 1-12. doi:10.1007/s11357-020-00226-9 Link

Németh, B., Goettsch, W., Kristensen, F. B., Pinyazhko, O., Huić, M., Tesař, T., Atanasijevic, D., Lipska, I., & Kaló, Z. (2020). The transferability of health technology assessment - the European perspective with focus on central and Eastern European countries. Expert Rev Pharmacoecon Outcomes Res. doi:10.1080/14737167.2020.1779061 Link

Németh, B., & Kaló, Z. (2020). European cooperation in health technology assessment implementation: the perspective of Central and Eastern European countries. In: Future Medicine. https://doi.org/10.2217/cer-2020-0062 Link

Országh, E., Pitter, J. G., Kaló, Z., Vokó, Z., & Józwiak, Á. (2020). Retrospective cost-utility analysis of the Non-typhoidal Salmonella control programme in Hungary. Food Control, 107529. Link

Ozieranski P, Csanádi M, Rickard E, Mulinari E. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016). BMJ Open. 2020 Sep 19;10(9):e037351. doi: 10.1136/bmjopen-2020-037351. Link

Petykó, Z. I., Inotai, A., Holtorf, A.-P., Brixner, D., & Kaló, Z. (2020). Barriers and facilitators of exploiting the potential of value-added medicines. Expert Review of Pharmacoeconomics & Outcomes Research doi: 10.1080/14737167.2020.1758558 Link

Rais, C., Kaló, Z., Csanádi, M., & Negulescu, V. (2020). Current and future perspectives for the implementation of health technology assessment in Romania. Health Policy and Technology, 9(1), 45-52. DOI: 10.1016/j.hlpt.2019.11.007 Link

Rutten-van Mölken, M., Karimi, M., Leijten, F., Hoedemakers, M., Looman, W., Islam, K., Askildsen, J. E., Kraus, M., Ercevic, D., Struckmann, V., Gyorgy Pitter, J., Cano, I., Stokes, J., & Jonker, M. (2020). Comparing patients’ and other stakeholders’ preferences for outcomes of integrated care for multimorbidity: a discrete choice experiment in eight European countries. BMJ Open, 10(10), e037547. doi:10.1136/bmjopen-2020-037547 Link

Vokó, Z., & Pitter, J. G. (2020). The effect of social distance measures on COVID-19 epidemics in Europe: an interrupted time series analysis. GeroScience, 1–8. Advance online publication. https://doi.org/10.1007/s11357-020-00205-0 Link

Vokó, Z., Bitter, I., Mersich, B., Réthelyi, J., Molnár, A., Pitter, J. G., Götze, Á., Horváth, M., Kóczián, K., Fonticoli, L., Lelli, F., & Németh, B. (2020). Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine. Cost Effectiveness and Resource Allocation, 18(1), 28. doi:10.1186/s12962-020-00224-w Link

Zemplényi, A. T., Csikós, Á., Csanádi, M., Mölken, M. R.-v., Hernandez, C., Pitter, J. G., Czypionka, T., Kraus, M., & Kaló, Z. (2020). Implementation of palliative care consult Service in Hungary – integration barriers and facilitators. BMC Palliative Care, 19(1). doi:10.1186/s12904-020-00541-0 Link

Zemplényi, A. T., Csikós, Á., Fadgyas-Freyler, P., Csanádi, M., Kaló, Z., Pozsgai, É., Rutten-van Mölken, M., & Pitter, J. G. (2020). Care Integration Decreases Hospitalization Costs: Retrospective Cohort Study of Palliative Care Consult Service for Hospital Patients With Metastatic Cancer. doi:10.21203/rs.3.rs-41113/v1 Link

2019

Abdullah, A. H., Holtorf, A.-P., Al-Hussaini, M., Lemay, J., Alowayesh, M., & Kaló, Z. (2019). Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait. Journal of pharmaceutical policy and practice, 12, 9-9. doi:10.1186/s40545-019-0171-4 Link

Agh, T., Csanadi, M., Voko, Z., Webb, T., Jeyakumaran, D., Trudeau, J., Sengupta, N., Schain, F., & Mattsson, J. (2019). Humanistic burden of patients with chronic graft-versus-host disease-systematic literature review of health-related quality of life and functional status. Expert review of hematology, 12(5), 295-309. Link

Almási, T., Guey, L. T., Lukacs, C., Csetneki, K., Vokó, Z., & Zelei, T. (2019). Systematic literature review and meta-analysis on the epidemiology of propionic acidemia. Orphanet Journal of Rare Diseases, 14(1). doi:10.1186/s13023-018-0987-z Link

Almási, T., Guey, L. T., Lukacs, C., Csetneki, K., Vokó, Z., & Zelei, T. (2019). Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency. Orphanet Journal of Rare Diseases, 14(1). doi:10.1186/s13023-019-1063-z Link

Baltaxe, E., Czypionka, T., Kraus, M., Reiss, M., Askildsen, J. E., Grenkovic, R., Lindén, T. S., Pitter, J. G., Rutten-van Molken, M., Solans, O., Stokes, J., Struckmann, V., Roca, J., & Cano, I. (2019). Digital Health Transformation of Integrated Care in Europe: Overarching Analysis of 17 Integrated Care Programs. Journal of Medical Internet Research, 21(9), e14956. doi:10.2196/14956 Link

Bogos, K., Kiss, Z., Gálffy, G., Tamási, L., Ostoros, G., Müller, V., Urbán, L., Bittner, N., Sárosi, V., Vastag, A., Polányi, Z., Nagy-Erdei, Z., Vokó, Z., Nagy, B., Horváth, K., Rokszin, G., Abonyi-Tóth, Z., & Moldvay, J. (2019). Revising Incidence and Mortality of Lung Cancer in Central Europe: An Epidemiology Review From Hungary. Frontiers in Oncology, 9. doi:10.3389/fonc.2019.01051 Link

Csanadi, M., Agh, T., Tordai, A., Webb, T., Jeyakumaran, D., Sengupta, N., Schain, F., & Mattsson, J. (2019). A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. Expert Review of Hematology, 12(5), 311-323. doi:10.1080/17474086.2019.1605288 Link

Csanádi, M., Inotai, A., Oleshchuk, O., Lebega, O., Alexandra, B., Piniazhko, O., Németh, B., & Kaló, Z. (2019). Health Technology Assessment Implementation in Ukraine: Current Status and Future Perspectives. International Journal of Technology Assessment in Health Care, 35(5), 393-400. doi:10.1017/s0266462319000679 Link

Csanádi, M., Löblová, O., Ozierański, P., Harsányi, A., Kaló, Z., McKee, M., & King, L. (2018). When health technology assessment is confidential and experts have no power: the case of Hungary. Health Economics, Policy and Law, 14(2), 162-181. doi:10.1017/s1744133118000051. Link

Csanádi, M., de Kok, I. M. C. M., Heijnsdijk, E. A. M., Anttila, A., Heinävaara, S., Pitter, J. G., Széles, G., Ivanuš, U., Priaulx, J., Veerus, P., Senore, C., Koning, H. J. d., & Vokó, Z. (2019). Key indicators of organized cancer screening programs: Results from a Delphi study. Journal of Medical Screening, 26(3), 120-126. doi:10.1177/0969141318820362 Link

Csanádi, M., Ozierański, P., Löblová, O., King, L., Kaló, Z., & Botz, L. (2019). Shedding light on the HTA consultancy market: Insights from Poland. Health Policy, 123(12), 1237-1243. doi:10.1016/j.healthpol.2019.08.008 Link

Freijer, K., Volger, S., Pitter, J. G., Molsen-David, E., Cooblall, C., Evers, S., Hiligsmann, M., Danel, A., & Lenoir-Wijnkoop, I. (2019). Medical Nutrition Terminology and Regulations in the United States and Europe—A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group. Value in Health, 22(1), 1-12. doi:10.1016/j.jval.2018.07.879 Link

Harsányi, A., Csanádi, M., Márky, K., Vincziczki, Á. Z., Kaló, Z., & Inotai, A. (2019). Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary. Expert Review of Pharmacoeconomics & Outcomes Research, 1-7. doi:10.1080/14737167.2019.1667232 Link

Holtorf, A.-P., Gialama, F., Wijaya, K. E., & Kaló, Z. (2019). External Reference Pricing for Pharmaceuticals—A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage. Value in Health Regional Issues, 19, 122-131. doi:10.1016/j.vhri.2019.04.003 Link

Inotai, A., & Kaló, Z. (2019). How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries?–the good, the bad, and the ugly ways. Expert Review of Pharmacoeconomics & Outcomes Research, 19(6), 627-632. Link

Kaló, Z., van den Akker, L. H. M., Vokó, Z., Csanádi, M., & Pitter, J. G. (2019). Is there a fair allocation of healthcare research funds by the European Union? PLOS ONE, 14(4), e0207046. doi:10.1371/journal.pone.0207046 Link

Lukács, G., Kovács, Á., Csanádi, M., Moizs, M., Repa, I., Kaló, Z., Vokó, Z., & Pitter, J. G. (2019). Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence. Cancer Management and Research, Volume 11, 9849-9861. doi:10.2147/cmar.s221427.Link

Löblová, O., Csanádi, M., Ozierański, P., Kaló, Z., King, L., & McKee, M. (2019). Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology. Health Policy, 123(7), 630-634. Link

Löblová, O., Csanádi, M., Ozierański, P., Kaló, Z., King, L., & McKee, M. (2019). Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016. Health Policy, 123(8), 713-720. doi:10.1016/j.healthpol.2019.05.021 Link

Németh, B., Bendes, R., Nagy, B., Götze, Á., Kóczián, K., Horváth, M., Deák, I., Tóth, B., & Kaló, Z. (2019). Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. Health Policy and Technology, 8(1), 84-91. doi:10.1016/j.hlpt.2019.01.004 Link

Németh, B., Molnár, A., Bozóki, S., Wijaya, K., Inotai, A., Campbell, J. D., & Kaló, Z. (2019). Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries. Journal of Comparative Effectiveness Research, 8(4), 195-204. doi:10.2217/cer-2018-0102 Link

Pednekar, P. P., Ágh, T., Malmenäs, M., Raval, A. D., Bennett, B. M., Borah, B. J., Hutchins, D. S., Manias, E., Williams, A. F., Hiligsmann, M., Turcu-Stiolica, A., Zeber, J. E., Abrahamyan, L., Bunz, T. J., & Peterson, A. M. (2019). Methods for Measuring Multiple Medication Adherence: A Systematic Review–Report of the ISPOR Medication Adherence and Persistence Special Interest Group. Value in Health, 22(2), 139-156. doi:10.1016/j.jval.2018.08.006 Link

Pitter, J. G., Csanádi, M., Szigeti, A., Lukács, G., Kovács, Á., Moizs, M., Repa, I., Zemplényi, A., Czypionka, T., Kraus, M., Rutten-van Mölken, M. P. M. H., & Kaló, Z. (2019). Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. BMC Health Services Research, 19(1). doi:10.1186/s12913-019-3957-9 Link

Tesar, T., Obsitnik, B., Kaló, Z., & Kristensen, F. B. (2019). How changes in reimbursement practices influence the financial sustainability of medicine policy: lessons learned from Slovakia. Frontiers in Pharmacology, 10, 664. doi: 10.3389/fphar.2019.00664 Link

Szilberhorn, L., Kaló, Z., & Ágh, T. (2019). Cost-effectiveness of second-generation direct-acting antiviral agents in chronic HCV infection: a systematic literature review. Antiviral Therapy, 24(4), 247-259. doi:10.3851/imp3290 Link

Szilberhorn, L., Kőrösi, L., Vajer, P., Nagy, B., & Vokó, Z. (2019). Cost-effectiveness of introducing licensed GP practices to manage diabetes patients in Hungary. Primary Care Diabetes, 13(5), 462-467. doi:10.1016/j.pcd.2019.03.004 Link

2018

Ágh, T., Gáspár, K., Nagy, B., Lehmann, M., & Kaló, Z. (2018). The value of a child born in the European Union. Acta Oeconomica, 68(2), 295-309. doi:10.1556/032.2018.68.2.6 Link

Begum, M., Lewison, G., Jassem, J., Mixich, V., Cufer, T., Nurgozhin, T., Shabalkin, P., Kutluk, T., Voko, Z., Radosavljevic, D., Vrdoljiak, E., Eniu, A., Walewski, J., Aggarwal, A., Lawler, M., & Sullivan, R. (2018). Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. European Journal of Cancer, 104, 127-136. doi:10.1016/j.ejca.2018.08.024 Link

Bochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Besovic, Z., Vella Bonanno, P., Bucsics, A., Davidescu, M., De Weerdt, E., Duborija-Kovacevic, N., Fürst, J., Gaga, M., Gailīte, E., Gulbinovič, J., Gürpınar, E. U., Hankó, B., Hargaden, V., Hotvedt, T. A., Hoxha, I., Huys, I., Inotai, A., Jakupi, A., Jenzer, H., Joppi, R., Laius, O., Lenormand, M.-C., Makridaki, D., Malaj, A., Margus, K., Marković-Peković, V., Miljković, N., de Miranda, J. L., Primožič, S., Rajinac, D., Schwartz, D. G., Šebesta, R., Simoens, S., Slaby, J., Sović-Brkičić, L., Tesar, T., Tzimis, L., Warmińska, E., & Godman, B. (2018). Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. Frontiers in Pharmacology, 8. doi:10.3389/fphar.2017.00942 Link

Brixner, D., Kaló, Z., Maniadakis, N., Kim, K., & Wijaya, K. (2018). An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets. Value in Health Regional Issues, 16, 9-13. doi:10.1016/j.vhri.2018.01.003 Link

Campbell, J. D., & Kaló, Z. (2018). Fair global drug pricing. Expert Review of Pharmacoeconomics & Outcomes Research, 18(6), 581-583. doi:10.1080/14737167.2018.1524296 Link

Csanádi, M., Kaló, Z., Prins, C. P. J., Grélinger, E., Menczelné Kiss, A., Fricke, F.-U., Fuksa, L., Tesar, T., Manova, M., Lorenzovici, L., Vokó, Z., & Garrison, L. P. (2018). The implications of external price referencing on pharmaceutical list prices in Europe. Health Policy and Technology, 7(3), 243-250. doi:10.1016/j.hlpt.2018.07.005 Link

Fasseeh, A., Németh, B., Molnár, A., Fricke, F. U., Horváth, M., Kóczián, K., Götze, Á., & Kaló, Z. (2018). A systematic review of the indirect costs of schizophrenia in Europe. European Journal of Public Health, 28(6), 1043-1049. doi:10.1093/eurpub/cky231 Link

Gyulai, A., Nagy, A., Pataki, V., Tonté, D., Ádány, R., & Vokó, Z. (2018). General practitioners can increase participation in cervical cancer screening – a model program in Hungary. BMC Family Practice, 19(1). doi:10.1186/s12875-018-0755-0 Link

Inotai, A., Ágh, T., Karpenko, A. W., Zemplényi, A., & Kaló, Z. (2018). Behind the subcutaneous trastuzumab hype: evaluation of benefits and their transferability to Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research, 19(2), 105-113. doi:10.1080/14737167.2019.1554437 Link

Inotai, A., Nguyen, H. T., Hidayat, B., Nurgozhin, T., Kiet, P. H. T., Campbell, J. D., Németh, B., Maniadakis, N., Brixner, D., Wijaya, K., & Kaló, Z. (2018). Guidance toward the implementation of multicriteria decision analysis framework in developing countries. Expert Review of Pharmacoeconomics & Outcomes Research, 18(6), 585-592. doi:10.1080/14737167.2018.1508345 Link

Inotai, A., Csanadi, M., Petrova, G., Dimitrova, M., Bochenek, T., Tesar, T., York, K., Fuksa, L., Kostyuk, A., Lorenzovici, L., Omelyanovskiy, V., Egyed, K., & Kalo, Z. (2018). Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed Research International, 2018, 1-9. doi:10.1155/2018/9597362 Link

Inotai, A., Brixner, D., Maniadakis, N., Dwiprahasto, I., Kristin, E., Prabowo, A., Yasmina, A., Priohutomo, S., Németh, B., Wijaya, K., & Kalo, Z. (2018). Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia. BMC health services research, 18(1), 1003-1003. doi:10.1186/s12913-018-3805-3 Link

Kamusheva, M., Manova, M., Savova, A. T., Petrova, G. I., Mitov, K., Harsányi, A., Kaló, Z., Márky, K., Kawalec, P., Angelovska, B., Lakić, D., Tesar, T., Draganic, P., Geitona, M., Hatzikou, M., Paveliu, M. S., & Männik, A. (2018). Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. Frontiers in Pharmacology, 9. doi:10.3389/fphar.2018.00795 Link

Kolasa, K., Zwolinski, K. M., Zah, V., Kaló, Z., & Lewandowski, T. (2018). Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis. Orphanet Journal of Rare Diseases, 13(1). doi:10.1186/s13023-018-0803-9 Link

Kovács, G., Almási, T., Millier, A., Toumi, M., Horváth, M., Kóczián, K., Götze, À., Kaló, Z., & Zemplényi, A. T. (2018). Direct healthcare cost of schizophrenia – European overview. European Psychiatry, 48(1), 79-92. doi:10.1016/j.eurpsy.2017.10.008 Link

Kulchaitanaroaj, P., Kaló, Z., West, R., Cheung, K. L., Evers, S., Vokó, Z., Hiligsmann, M., de Vries, H., Owen, L., Trapero-Bertran, M., Leidl, R., & Pokhrel, S. (2018). Understanding perceived availability and importance of tobacco control interventions to inform European adoption of a UK economic model: a cross-sectional study. BMC Health Services Research, 18(1). doi:10.1186/s12913-018-2923-2 Link

Leijten, F. R. M., Hoedemakers, M., Struckmann, V., Kraus, M., Cheraghi-Sohi, S., Zemplényi, A., Ervik, R., Vallvé, C., Huiĉ, M., Czypionka, T., Boland, M., & Rutten-van Mölken, M. P. M. H. (2018). Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. BMJ Open, 8(8), e021072. doi:10.1136/bmjopen-2017-021072 Link

Németh, B., Józwiak-Hagymásy, J., Kovács, G., Kovács, A., Demjén, T., Huber, M. B., Cheung, K.-L., Coyle, K., Lester-George, A., Pokhrel, S., & Vokó, Z. (2018). Cost-effectiveness of possible future smoking cessation strategies in Hungary: results from the EQUIPTMOD. Addiction, 113, 76-86. doi:10.1111/add.14089 Link

Németh, B., Fasseeh, A., Molnár, A., Bitter, I., Horváth, M., Kóczián, K., Götze, Á., & Nagy, B. (2018). A systematic review of health economic models and utility estimation methods in schizophrenia. Expert Review of Pharmacoeconomics & Outcomes Research, 18(3), 267-275. doi:10.1080/14737167.2018.1430571 Link

Németh, B., Kulchaitanaroaj, P., Lester-George, A., Huic, M., Coyle, K., Coyle, D., Pokhrel, S., & Kaló, Z. (2018). A utility of model input uncertainty analysis in transferring tobacco control-related economic evidence to countries with scarce resources: results from the EQUIPT study. Addiction, 113, 42-51. doi:10.1111/add.14092 Link

Nestler-Parr, S., Korchagina, D., Toumi, M., Pashos, C. L., Blanchette, C., Molsen, E., Morel, T., Simoens, S., Kaló, Z., Gatermann, R., & Redekop, W. (2018). Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. Value in Health, 21(5), 493-500. doi:10.1016/j.jval.2018.03.004 Link

Ozierański, P., Löblová, O., Nicholls, N., Csanádi, M., Kaló, Z., McKee, M., & King, L. (2018). Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015. Health Economics, Policy and Law, 14(2), 182-204. doi:10.1017/s1744133117000342 Link

Pitter, J. G., Vokó, Z., Józwiak, Á., & Berkics, A. (2018). Campylobacter control measures in indoor broiler chicken: critical re-assessment of cost-utility and putative barriers to implementation. Epidemiology and Infection, 146(11), 1433-1444. doi:10.1017/s0950268818001528 Link

Pitter, J. G., Lukács, G., Csanádi, M., & Vokó, Z. (2018). Clinical impact of treatment delay in pancreatic cancer patients revisited. International Journal of Cancer, 142(12), 2621-2622. doi:10.1002/ijc.31263 Link

Priaulx, J., Csanádi, M., de Koning, H. J., & McKee, M. (2018). A choice experiment to identify the most important elements of a successful cancer screening program according to those who research and manage such programs. The International Journal of Health Planning and Management, 34(1), e34-e45. doi:10.1002/hpm.2697 Link

Priaulx, J., de Koning, H. J., de Kok, I. M. C. M., Széles, G., & McKee, M. (2018). Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST). Health Policy, 122(11), 1190-1197. doi:10.1016/j.healthpol.2018.08.004 Link

Rutten- van Molken, M., Leijten, F., Hoedemakers, M., Tsicahristas, A., Verbeek, N., Bal, R., De Bont, A., Islam, K., Askildsen, J.-E., Czypionka, T., Huic, M., Pitter, J., Vogt, V., Stokes, J., & Baltaxe, E. (2018). Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analyses MCDA. International Journal of Integrated Care, 18(s2), 315. doi:10.5334/ijic.s2315 Link

Szegedi, M., Zelei, T., Arickx, F., Bucsics, A., Cohn-Zanchetta, E., Fürst, J., Kamusheva, M., Kawalec, P., Petrova, G., Slaby, J., Stawowczyk, E., Vocelka, M., Zechmeister-Koss, I., Kaló, Z., & Molnár, M. J. (2018). The European challenges of funding orphan medicinal products. Orphanet Journal of Rare Diseases, 13(1). doi:10.1186/s13023-018-0927-y Link

Trapero-Bertran, M., Muñoz, C., Coyle, K., Coyle, D., Lester-George, A., Leidl, R., Németh, B., Cheung, K.-L., Pokhrel, S., & Lopez-Nicolás, Á. (2018). Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD. Addiction, 113, 65-75. doi:10.1111/add.14090 Link

Turnbull, E., Priaulx, J., van Ravesteyn, N. T., Heinävaara, S., Siljander, I., Senore, C., Segnan, N., Vokó, Z., Hagymásy, J., Jarm, K., Veerus, P., de Koning, H. J., & McKee, M. (2018). A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries. Health Policy, 122(11), 1198-1205. doi:10.1016/j.healthpol.2018.08.003 Link

Turnbull, E., Priaulx, J., de Kok, I. M. C. M., Lansdorp-Vogelaar, I., Anttila, A., Sarkeala, T., Senore, C., Segnan, N., Csanádi, M., Pitter, J., Novak Mlakar, D., Ivanus, U., Veerus, P., de Koning, H. J., & McKee, M. (2018). Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries. Health Policy, 122(11), 1206-1211. doi:10.1016/j.healthpol.2018.08.005 Link

Zelei, T., Csetneki, K., Vokó, Z., & Siffel, C. (2018). Epidemiology of Sanfilippo syndrome: results of a systematic literature review. Orphanet Journal of Rare Diseases, 13(1). doi:10.1186/s13023-018-0796-4 Link

2017

Brixner, D., Maniadakis, N., Kaló, Z., Hu, S., Shen, J., & Wijaya, K. (2017). Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. Value in Health Regional Issues, 13, 1-6. doi:10.1016/j.vhri.2017.02.001 Link

Coyle, K., Coyle, D., Lester-George, A., West, R., Nemeth, B., Hiligsmann, M., Trapero-Bertran, M., Leidl, R., & Pokhrel, S. (2017). Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation. Addiction, 113, 7-18. doi:10.1111/add.14001 Link

Elek, P., Harsányi, A., Zelei, T., Csetneki, K., & Kaló, Z. (2017). Policy objective of generic medicines from the investment perspective: The case of clopidogrel. Health Policy, 121(5), 558-565. doi:10.1016/j.healthpol.2017.02.015 Link

Elek, P., Takács, E., Merész, G., & Kaló, Z. (2016). Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries. Health Policy and Planning, czw133. doi:10.1093/heapol/czw133 Link

Huber, M. B., Präger, M., Coyle, K., Coyle, D., Lester-George, A., Trapero-Bertran, M., Nemeth, B., Cheung, K. L., Stark, R., Vogl, M., Pokhrel, S., & Leidl, R. (2017). Cost-effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD. Addiction, 113, 52-64. doi:10.1111/add.14062 Link

Inotai, A., Csanádi, M., Harsányi, A., & Németh, B. (2017). Drug Policy in Hungary. Value in Health Regional Issues, 13, 16-22. doi:10.1016/j.vhri.2017.06.003 Link

Inotai A, Csanadi M, Vitezic D, Francetic I, Tesar T, Bochenek T, Lorenzovici L, Dylst P, Kalo Z.(2017). Policy Practices to Maximise Social Benefit from Biosimilars. Journal of Bioequivalence & Bioavailability, 09(04). doi:10.4172/jbb.1000346 Link

Inotai, A., Prins, C. P. J., Csanádi, M., Vitezic, D., Codreanu, C., & Kaló, Z. (2017). Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opinion on Biological Therapy, 17(8), 915-926. doi:10.1080/14712598.2017.1341486 Link

Kalo, Z., Abonyi-Tóth, Z., Rokszin, G., Ágh, T., & Inotai, A. (2017). Impact of multiple switching on health care costs and outcomes in generic drug policies: The Hungarian case of losartan. Acta Poloniae Pharmaceutica-Drug Research, 74(4), 1295-1300. Link

Kaló, Z., Vokó, Z., Östör, A., Clifton-Brown, E., Vasilescu, R., Battersby, A., & Gibson, E. (2017). Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. Journal of Market Access & Health Policy, 5(1), 1345580. doi:10.1080/20016689.2017.1345580 Link

Kawalec, P., Tesar, T., Vostalova, L., Draganic, P., Manova, M., Savova, A., Petrova, G., Rugaja, Z., Männik, A., Sowada, C., Stawowczyk, E., Harsanyi, A., Inotai, A., Turcu-Stiolica, A., Gulbinovič, J., & Pilc, A. (2017). Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Frontiers in Pharmacology, 8. doi:10.3389/fphar.2017.00892 Link

Kovács, G., Somogyvári, Z., Maka, E., & Nagyjánosi, L. (2017). Bedside ROP screening and telemedicine interpretation integrated to a neonatal transport system: Economic aspects and return on investment analysis. Early Human Development, 106-107, 1-5. doi:10.1016/j.earlhumdev.2017.01.007 Link

Molnár, A., Nagy, B., Kerpel-Fronius, A., Bajzik, G., Horváth, I., Moizs, M., & Vokó, Z. (2017). Modelling Patient Pathways Of Low-Dose Computed Tomography Screening For Lung Cancer In Hungary. Value in Health, 20(9), A750. doi:10.1016/j.jval.2017.08.2096 Link

Nagy B, Setyawan J, Coghill D, Soroncz-Szabo T, Kalo Z, Doshi JA. A conceptual framework for a long-term economic model of the treatment of attention-deficit/hyperactivity disorder. EXPERT REV PHARMACOECON OUTCOMES RES 17. 3. 283-292. (2017) Link

Narbutas, Š., York, K., Stein, B. D., Magsanoc-Alikpala, K., Majima, Y., Kalo, Z., Almasi, T., & Inotai, A. (2017). Overview on Patient Centricity in Cancer Care. Frontiers in Pharmacology, 8. doi:10.3389/fphar.2017.00698 Link

Németh, B., Csanádi, M., & Kaló, Z. (2017). Overview on the current implementation of health technology assessment in the healthcare system in Hungary. International Journal of Technology Assessment in Health Care, 33(3), 333-338. doi:10.1017/s0266462317000071 Link

Németh, B., Molnár, A., Akehurst, R., Horváth, M., Kóczián, K., Németh, G., Götze, Á., & Vokó, Z. (2017). Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. Journal of Comparative Effectiveness Research, 6(8), 639-648. doi:10.2217/cer-2017-0024 Link

Pitter, J. G., Horváth, B., Abonyi-Tóth, Z., Rokszin, G., Fadgyas-Freyler, P., Kovács, G., Ács, N., Kaló, Z., & Vokó, Z. (2017). Drug-associated miscarriage, teratogenicity and low birthweight risks: Methods for population-based case–control studies in Hungary. Reproductive Toxicology, 72, 26. doi:10.1016/j.reprotox.2017.06.064 Link

Rosselli, D., Quirland-Lazo, C., Csanádi, M., Ruiz de Castilla, E. M., González, N. C., Valdés, J., Abicalaffe, C., Garzón, W., Leon, G., & Kaló, Z. (2017). HTA Implementation in Latin American Countries: Comparison of Current and Preferred Status. Value in Health Regional Issues, 14, 20-27. doi:10.1016/j.vhri.2017.02.004 Link

Tesar, T., Szilberhorn, L., Nemeth, B., Nagy, B., Wawruch, M., & Kalo, Z. (2017). Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer. Frontiers in Pharmacology, 8. doi:10.3389/fphar.2017.00946 Link

Vokó, Z., Gáspár, K., Inotai, A., Horváth, C., Bors, K., Speer, G., & Kaló, Z. (2017). Osteoporotic fractures may impair life as much as the complications of diabetes. Journal of Evaluation in Clinical Practice, 23(6), 1375-1380. doi:10.1111/jep.12800 Link

2016

Ágh, T., Kovács, G., Supina, D., Pawaskar, M., Herman, B. K., Vokó, Z., & Sheehan, D. V. (2016). A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 21(3), 353-364. doi:10.1007/s40519-016-0264-x Link

Ágh, T., Pawaskar, M., Nagy, B., Lachaine, J., & Vokó, Z. (2016). The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA. Clinical Drug Investigation, 36(4), 305-312. doi:10.1007/s40261-016-0381-3 Link

Bodnár, R., Meszaros, A., Olah, M., & Agh, T. (2016). Inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes. Patient Preference and Adherence, 183. doi:10.2147/ppa.s53653 Link

Cheung, K. L., Evers, S. M. A. A., Hiligsmann, M., Vokó, Z., Pokhrel, S., Jones, T., Muñoz, C., Wolfenstetter, S. B., Józwiak-Hagymásy, J., & de Vries, H. (2016). Understanding the stakeholders’ intention to use economic decision-support tools: A cross-sectional study with the tobacco return on investment tool. Health Policy, 120(1), 46-54. doi:10.1016/j.healthpol.2015.11.004 Link

Glonti, K., Pitter, J., Csanadi, M., Vokó, Z., & McKee, M. (2016). Health system factors associated with uptake of cancer screening: an overview of systematic reviews. European Journal of Public Health, 26(suppl_1). doi:10.1093/eurpub/ckw169.068 Link

Kaló, Z., Gheorghe, A., Huic, M., Csanádi, M., & Kristensen, F. B. (2016). HTA Implementation Roadmap in Central and Eastern European Countries. Health Economics, 25, 179-192. doi:10.1002/hec.3298 Link

Kaló, Z., Vokó, Z., Akhras, K. S., & Kanavos, P. (2016). Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries. Expert Review of Pharmacoeconomics & Outcomes Research, 16(1), 15-16. doi:10.1586/14737167.2016.1136792 Link

Kaló, Z., Vokó, Z., Clifton-Brown, E., Vasilescu, R. S., David, T., Gibson, E., Begum, N., & Rao, N. (2016). Impact of National Criteria and Healthcare System Characteristics on Access to Biologic Dmards in Rheumatoid Arthritis In Europe. Value in Health, 19(7), A547-A548. doi:10.1016/j.jval.2016.09.1163 Link

Kolasa, K., Zwolinski, K. M., Kalo, Z., & Hermanowski, T. (2016). Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. Orphanet Journal of Rare Diseases, 11(1). doi:10.1186/s13023-016-0388-0 Link

Kolasa, K., Kalo, Z., & Zah, V. (2016). The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations. Expert Review of Pharmacoeconomics & Outcomes Research, 16(4), 483-488. doi:10.1080/14737167.2016.1215917 Link

Kovács, G., Zelei, T., & Vokó, Z. (2016). Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis. Climacteric, 19(5), 488-495. doi:10.1080/13697137.2016.1221919 Link

Marsh, K., Ijzerman, M., Thokala, P., Baltussen, R., Boysen, M., Kaló, Z., Lönngren, T., Mussen, F., Peacock, S., Watkins, J., & Devlin, N. (2016). Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value in Health, 19(2), 125-137. doi:10.1016/j.jval.2015.12.016 Link

Nagy, B., Zsólyom, A., Nagyjánosi, L., Merész, G., Steiner, T., Papp, E., Dessewffy, Z., Jermendy, G., Winkler, G., Kaló, Z., & Vokó, Z. (2016). Cost-effectiveness of a risk-based secondary screening programme of type 2 diabetes. Diabetes/Metabolism Research and Reviews, 32(7), 710-729. doi:10.1002/dmrr.2791 Link

Nagy, B., Setyawan, J., Coghill, D., Soroncz-Szabó, T., Kaló, Z., & Doshi, J. A. (2016). A conceptual framework for a long-term economic model for the treatment of attention-deficit/hyperactivity disorder. Expert Review of Pharmacoeconomics & Outcomes Research, 17(3), 283-292. doi:10.1080/14737167.2017.1271325 Link

Vokó, Z., Cheung, K. L., Józwiak-Hagymásy, J., Wolfenstetter, S., Jones, T., Muñoz, C., Evers, S. M. A. A., Hiligsmann, M., de Vries, H., & Pokhrel, S. (2016). Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey. Health Research Policy and Systems, 14(1). doi:10.1186/s12961-016-0110-7 Link

Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, Longrenn T, Mussen F, Peacock S, Watkins J, Ijzerman M. Multiple Criteria Decision Analysis for Health Care Decision Making-An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016. 19(1). 1-13.

Zelei, T., Molnár, M. J., Szegedi, M., & Kaló, Z. (2016). Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. Orphanet Journal of Rare Diseases, 11(1). doi:10.1186/s13023-016-0455-6 Link

Zemplenyi AT, Mangel L, Kalo Z, Endrei D, Lohner S, Boncz I. Meta-analysis of the side-effect profiles of modern radiation therapies for patients with prostate cancer (Article in Hungarian). ORVOSI HETILAP 157(20):776-88. (2016) Link

Zemplényi, A. T., Kaló, Z., Kovács, G., Farkas, R., Beöthe, T., Bányai, D., Sebestyén, Z., Endrei, D., Boncz, I., & Mangel, L. (2016). Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. European Journal of Cancer Care, 27(1), e12430. doi:10.1111/ecc.12430 Link

2015

Ágh, T., Bodnár, R., Oláh, M., & Mészáros, Á. (2015). Adherence to Inhaled Antibiotics for The Treatment of Chronic Pseudomonas Aeruginosa Infection In Patients With Cystic Fibrosis: A Systematic Literature Review. Value in Health, 18(7), A760. doi:10.1016/j.jval.2015.09.2480 Link

Ágh, T., Kovács, G., Pawaskar, M., Supina, D., Inotai, A., & Vokó, Z. (2015). Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 20(1), 1-12. doi:10.1007/s40519-014-0173-9 Link

Ágh, T., Dömötör, P., Bártfai, Z., Inotai, A., Fujsz, E., & Mészáros, Á. (2015). Relationship between medication adherence and health-related quality of life in subjects with COPD: a systematic review. Respiratory care, 60(2), 297-303. Link

Drummond, M., Augustovski, F., Kaló, Z., Yang, B.-M., Pichon-Riviere, A., Bae, E.-Y., & Kamal-Bahl, S. (2015). CHALLENGES FACED IN TRANSFERRING ECONOMIC EVALUATIONS TO MIDDLE INCOME COUNTRIES. International Journal of Technology Assessment in Health Care, 31(6), 442-448. doi:10.1017/s0266462315000604 Link

Gyulai, A., Nagy, A., Pataki, V., Tonté, D., Ádány, R., & Vokó, Z. (2015). Survey of Participation in Organised Cervical Cancer-Screening Programme in Hungary. Cent Eur J Public Health, 23(4), 360-364. doi:10.21101/cejph.a4068 Link

Inotai, A., Abonyi-Tóth, Z., Rokszin, G., & Vokó, Z. (2015). Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary. Value in Health Regional Issues, 7, 1-8. doi:10.1016/j.vhri.2015.03.020 Link

Kaló, Z., Alabbadi, I., Al Ahdab, O. G., Alowayesh, M., Elmahdawy, M., Al-Saggabi, A. H., Tanzi, V. L., Al-Badriyeh, D., Alsultan, H. S., Ali, F. M. H., Elsisi, G. H., Akhras, K. S., Vokó, Z., & Kanavos, P. (2015). Implications of external price referencing of pharmaceuticals in Middle East countries. Expert Review of Pharmacoeconomics & Outcomes Research, 15(6), 993-998. doi:10.1586/14737167.2015.1048227 Link

Kaló, Z., Holtorf, A.-P., Alfonso-Cristancho, R., Shen, J., Ágh, T., Inotai, A., & Brixner, D. (2015). Need for Multicriteria Evaluation of Generic Drug Policies. Value in Health, 18(2), 346-351. doi:10.1016/j.jval.2014.12.012 Link

Kind, P., & Vokó, Z. (2015). A National Eq-5d Value Set for Hungary - a Model Methodology ? Value in Health, 18(7), A738. doi:10.1016/j.jval.2015.09.2833 Link

Mandrik, O., Knies, S., Kalo, Z., & Severens, J. L. (2015). REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. International Journal of Technology Assessment in Health Care, 31(6), 434-441. doi:10.1017/s0266462315000677 Link

Nagy, B. (2015). Improving the allocation of health care resources in Poland. WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR EUROPE. Link

Oyebode, O., Garrett, Z., George, E., Cangini, A., Muscolo, L. A. A., Warren, S., Nemeth, B., Földesi, C., Heislerová, M., & Gajdošová, E. (2015). EVIDENCE REQUIREMENTS FOR REIMBURSEMENT OF PHARMACEUTICALS ACROSS EUROPE. International Journal of Technology Assessment in Health Care, 31(1-2), 59-67. doi:10.1017/s0266462315000227 Link

Pawaskar, M., Vokó, Z., Ágh, T., Sheehan, D. V., McElroy, S. L., Radewonuk, J., Merész, G., Herman, B. K., & Gasior, M. (2015). Longitudinal Modeling The Effect Of Lisdexamfetamine Dimesylate And Changes In Binge Eating Frequency On Disability In Patients With Binge Eating Disorder. Value in Health, 18(7), A407. doi:10.1016/j.jval.2015.09.959 Link

Pawaskar, M., Ágh, T., Radewonuk, J., Vokó, Z., McElroy, S. L., Herman, B. K., & Gasior, M. (2015). Longitudinal Modeling Of The Relationship Between Lisdexamfetamine Dimesylate And Health-Related Quality Of Life In Adults With Moderate To Severe Binge Eating Disorder. Value in Health, 18(7), A407. doi:10.1016/j.jval.2015.09.958 Link

Pitter J, Jozwiak A, Martos E, Kalo Z, Voko Z. Next steps to evidence-based food safety risk analysis: opportunities for health technology assessment methodology implementation. STUDIES IN AGRICULTURAL ECONOMICS 117. 155-161. (2015) Link

Pitter, J. G., Vokó, Z., Halmos, Á., & Józwiak, Á. (2015). Cost-Utility Analysis of Potential Campylobacter Control Measures in the Food Chain of Indoor Broiler Chicken in the Eu. Value in Health, 18(7), A649. doi:10.1016/j.jval.2015.09.2331 Link

Sebestyén, A., Mester, S., Vokó, Z., Gajdácsi, J., Cserháti, P., Speer, G., Patczai, B., Warta, V., Bódis, J., Horváth, C., & Boncz, I. (2015). Wintertime surgery increases the risk of conversion to hip arthroplasty after internal fixation of femoral neck fracture. Osteoporos Int, 26(3), 1109-1117. doi:10.1007/s00198-014-2966-0 Link

Voko Z, Beran D, Pusztai Zs, Bak Pedersen H, Evetovits T, Szigeti Sz. Better non-communicable disease outcomes: challenges and opportunities for health systems. Hungary Country Assessment: Focus on diabetes 2014. WHO REGIONAL OFFICE FOR EUROPE. (2015) Link

2014

Adany, R., & Voko, Z. (2014). Hungarian public health - ups and downs in the last 20 years. The European Journal of Public Health, 24(3), 352-353. doi:10.1093/eurpub/cku034 Link

Ágh, T., Pawaskar, M., Kovacs, G., Kalo, Z., Supina, D., & Voko, Z. (2014). The humanistic and economic burden of bulimia nervosa and binge eating disorder: A systematic literature review. Value in Health, 17(3), A213. doi:10.1016/j.jval.2014.03.1249 Link

Elsisi, G. H., Eldessouki, R., Kalo, Z., Elmazar, M. M., Taha, A. S., Awad, B. F., & El-Hamamsy, M. H. (2014). Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov Model. Value in Health Regional Issues, 4, 24-30. doi:10.1016/j.vhri.2014.06.004 Link

Gregory, V., Barbeau, M., Machnicki, G., Voko, Z., Heisel, O., & Keown, P. (2014). Real world research in latin america: Opportunities, sources and barriers. Value in Health, 17(3), A188. doi:10.1016/j.jval.2014.03.1099 Link

Inotai, A., Abonyi-Tóth, Z., Rokszin, G., & Voko, Z. (2014). Occurrence, Survival And Annual Cost of Colorectal-, Breast-, Prostate- and Lung Cancer in Hungary. Value in Health, 17(7), A553. doi:10.1016/j.jval.2014.08.1809 Link

Inotai, A., Petrova, G., Vitezic, D., & Kaló, Z. (2014). Benefits of investment into modern medicines in Central-Eastern European countries. Expert Rev Pharmacoecon Outcomes Res, 14(1), 71-79. doi:10.1586/14737167.2014.868314 Link

Kaló, Z., Antal, J., Pénzes, M., Pozsgay, C., Szepezdi, Z., & Nagyjánosi, L. (2014). Contribution of clinical trials to gross domestic product in Hungary. Croatian Medical Journal, 55(5), 446-451. doi:10.3325/cmj.2014.55.446 Link

Kolasa, K., Kaló, Z., & Hornby, E. (2014). Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices. Expert Review of Pharmacoeconomics & Outcomes Research, 15(1), 145-155. doi:10.1586/14737167.2014.898566 Link

Kovács, G., Kaló, Z., Jahnz-Rozyk, K., Kyncl, J., Csohan, A., Pistol, A., Leleka, M., Kipshakbaev, R., Durand, L., & Macabeo, B. (2014). Medical and economic burden of influenza in the elderly population in central and eastern European countries. Hum Vaccin Immunother, 10(2), 428-440. doi:10.4161/hv.26886 Link

Kwong, D., Ferrario, A., Adamski, J., Inotai, A., & Kaló, Z. (2014). Managing the introduction of new and high-cost drugs in challenging times: the experience of Hungary and Poland. EuroHealth, 20(2), 25-28. Link

Lorenzovici, L., Székely, A., Ágh, T., Vámossy, I., Kelemen, L. J., Finta, H., & Kaló, Z. (2014). Economic Evaluation of Ulipristal Acetate for the Treatment of Patients With Moderate and Severe Symptoms of Uterine Fibroids in Romania. Value in Health, 17(7), A510. doi:10.1016/j.jval.2014.08.1563 Link

Nagy, B., Timár, G., Józwiak-Hagymásy, J., Kovács, G., Merész, G., Vámossy, I., Ágh, T., László, Á., Vokó, Z., & Kaló, Z. (2014). The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. European Journal of Obstetrics & Gynecology and Reproductive Biology, 175, 75-81. doi:10.1016/j.ejogrb.2014.01.022 Link

Pokhrel, S., Evers, S., Leidl, R., Trapero-Bertran, M., Kalo, Z., Vries, H. d., Crossfield, A., Andrews, F., Rutter, A., Coyle, K., Lester-George, A., West, R., Owen, L., Jones, T., Vogl, M., Radu-Loghin, C., Voko, Z., Huic, M., & Coyle, D. (2014). EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. BMJ Open, 4(11), e006945. doi:10.1136/bmjopen-2014-006945 Link

Sebestyén, A., Mester, S., Vokó, Z., Gajdácsi, J., Cserháti, P., Speer, G., Patczai, B., Warta, V., Bódis, J., Horváth, C., & Boncz, I. (2014). Wintertime surgery increases the risk of conversion to hip arthroplasty after internal fixation of femoral neck fracture. Osteoporosis International, 26(3), 1109-1117. doi:10.1007/s00198-014-2966-0 Link

Strain, W. D., Cos, X., Hirst, M., Vencio, S., Mohan, V., Vokó, Z., Yabe, D., Blüher, M., & Paldánius, P. M. (2014). Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 105(3), 302-312. doi:10.1016/j.diabres.2014.05.005 Link

Vokó, Z., Németh, R., Nagyjánosi, L., Jermendy, G., Winkler, G., Hídvégi, T., Kalotai, Z., & Kaló, Z. (2014). Mapping the Nottingham Health Profile onto the Preference-Based EuroQol-5D Instrument for Patients with Diabetes. Value in Health Regional Issues, 4, 31-36. doi:10.1016/j.vhri.2014.06.002 Link

Vokó, Z., Beran, D., Pusztai, Z., Bak Pedersen, H., Evetovits, T., & Szigeti, S. (2014). Better non-communicable disease outcomes: challenges and opportunities for health systems. Hungary Country Assessment: Focus on diabetes. Link

Zsólyom, A., Nagy, B., Dessewffy, Z., Steiner, T., Kaló, Z., & Vokó, Z. (2014). Cost-effectiveness of the introduction of a risk stratified population screening for type 2 diabetes in hungary. Value in Health, 17(3), A259. doi:10.1016/j.jval.2014.03.1509 Link

Zsólyom, A., Nagy, B., Nagyjánosi, L., Dessewffy, Z., Steiner, T., Kaló, Z., & Vokó, Z. (2014). Cost-Effectiveness of Theintroduction of A National Adherence Program for Type 2 Diabetes In Hungary. Value in Health, 17(7), A358. doi:10.1016/j.jval.2014.08.770 Link

2013

Boncz, I., Kaló, Z., Mohamed Ibrahim, M. I. B., & Greenberg, D. (2013). Further Steps in the Development of Pharmacoeconomics, Outcomes Research, and Health Technology Assessment in Central and Eastern Europe, Western Asia, and Africa. Value in Health Regional Issues, 2(2), 169-170. doi:10.1016/j.vhri.2013.07.007 Link

Elsisi, G. H., Kaló, Z., Eldessouki, R., Elmahdawy, M. D., Saad, A., Ragab, S., Elshalakani, A. M., & Abaza, S. (2013). Recommendations for Reporting Pharmacoeconomic Evaluations in Egypt. Value in Health Regional Issues, 2(2), 319-327. doi:10.1016/j.vhri.2013.06.014 Link

Merész, G., Németh, B., & Sinkovits, B. (2013). Conference report. Acta Oeconomica, 63(3), 377-381. doi:10.1556/aoecon.63.2013.3.7 Link

Kaló, Z., Annemans, L., & Garrison, L. P. (2013). Differential pricing of new pharmaceuticals in lower income European countries. Expert Review of Pharmacoeconomics & Outcomes Research, 13(6), 735-741. doi:10.1586/14737167.2013.847367 Link

Kaló, Z., Bodrogi, J., Boncz, I., Dózsa, C., Jóna, G., Kövi, R., Pásztélyi, Z., & Sinkovits, B. (2013). Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary. Value in Health Regional Issues, 2(2), 264-266. doi:10.1016/j.vhri.2013.06.002 Link

Szabó, L., Jackowska, T., Kaló, Z., Kulcsár, A., Mészner, Z., Molnár, Z., Wysocki, J., Wutzler, P., Kormos-Tasi, J., & Sauboin, C. (2013). Varicella vaccination in Hungary and Poland: optimization of public benefits from prophylaxis technologies in the time of austerity. New Medicine. Link

Szabó, R. P., Klenk, N., Balla, J., Asztalos, L., Szabó, L., & Vokó, Z. (2013). Prognosis of Dialysed Patients after Kidney Transplant Failure. Kidney and Blood Pressure Research, 37(2-3), 151-157. doi:10.1159/000350140 Link

Voko, Z., Nemeth, R., Dank, M., Nagy-Erdei, Z., Kalo, Z., & Geczi, L. (2013). Mapping the Cancer-Specific EORTC QLQ-BR23 onto the Preference-Based EuroQol-5D Instrument. Journal of Health Policy and Outcomes Research(2), 90-99. Link

Zsólyom, A., Merész, G., Nagyjánosi, L., Nagyistók, S., Nagy, B., Kaló, Z., & Vokó, Z. (2013). External Validation of the Syreon Diabetes Model. Value in Health, 16(7), A590. doi:10.1016/j.jval.2013.08.1640 Link

2012

Borsos, G., Vokó, Z., Gredes, T., Kunert-Keil, C., & Vegh, A. (2012). Tooth movement using palatal implant supported anchorage compared to conventional dental anchorage. Annals of Anatomy - Anatomischer Anzeiger, 194(6), 556-560. doi:10.1016/j.aanat.2012.08.003 Link

Inotai, A., Agh, T., & Meszaros, A. (2012). Quality of life, utility and health burden in asthma, chronic obstructive pulmonary disease and rheumatoid arthritis. International Journal of Person Centered Medicine, 2(3), 505-510. Link

Inotai, A., & Meszaros, A. (2012). Determinants of NSAID choice in rheumatoid arthritis--a drug utilization study. Acta poloniae pharmaceutica, 69(4), 773-777. Link

Inotai A, Nagy B, Kalo Z: Biosimilars and evidence based decision making in Central Eastern European countries. [in Hungarian] ORVOSTOVABBKEPZO SZEMLE 19: 69-73. (2012) Link

Inotai, A., Nuijten, M., Roth, E., Hegazi, R., & Kaló, Z. (2012). Modelling the burden of disease associated malnutrition. e-SPEN Journal, 7(5), e196-e204. doi:10.1016/j.clnme.2012.07.003 Link

Inotai, A., Pékli, M., Jóna, G., Nagy, O., Remák, E., & Kaló, Z. (2012). Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. BMC Health Services Research, 12(1). doi:10.1186/1472-6963-12-332 Link

Kalo, Z., Abonyi-Toth, Z., Bartfai, Z., & Voko, Z. (2012). Pitfalls associated with the therapeutic reference pricing practice of asthma medication. BMC Pulmonary Medicine, 12(1). doi:10.1186/1471-2466-12-35 Link

Kaló, Z., Boncz, I., & Inotai, A. (2012). Implications of economic crisis on health care decision-making in Hungary: An opportunity to change. Journal of Health Policy and Outcomes Research, 1, 20-26. Link

Kaló, Z., Landa, K., DoleŽAl, T., & Vokó, Z. (2012). Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. European Journal of Cancer Care, 21(4), 442-449. doi:10.1111/j.1365-2354.2012.01351.x Link

Kolasa, K., Kalo, Z., Zah, V., & Dolezal, T. (2012). Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research, 12(3), 283-287. doi:10.1586/erp.12.12 Link

Nagy, B., Gaspar, I., Papp, A., Bene, Z., Nagy, B., Voko, Z., & Balla, G. (2012). Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatric Pulmonology, 48(2), 168-175. doi:10.1002/ppul.22574 Link

Papp, K., Végh, P., Hóbor, R., Szittner, Z., Vokó, Z., Podani, J., Czirják, L., & Prechl, J. (2012). Immune Complex Signatures of Patients with Active and Inactive SLE Revealed by Multiplex Protein Binding Analysis on Antigen Microarrays. PLoS ONE, 7(9), e44824. doi:10.1371/journal.pone.0044824 Link

Petrovski, B. É., Pataki, V., Jenei, T., Ádány, R., & Vokó, Z. (2012). Selenium levels in men with liver disease in Hungary. Journal of Trace Elements in Medicine and Biology, 26(1), 31-35. doi:10.1016/j.jtemb.2012.01.001 Link

Szigethy, E., Széles, G., Horváth, A., Hidvégi, T., Jermendy, G., Paragh, G., Blaskó, G., Ádány, R., & Vokó, Z. (2012). Epidemiology of the metabolic syndrome in Hungary. Public Health, 126(2), 143-149. doi:10.1016/j.puhe.2011.11.003 Link

Vokó, Z., Nagyjánosi, L., & Kaló, Z. (2012). Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health, 12(1). doi:10.1186/1471-2458-12-924 Link

Vokó, Z., Nagyjánosi, L., Margitai, B., Kövi, R., Tóth, Z., László, D., & Kaló, Z. (2012). Modeling Cost-Effectiveness of Cervical Cancer Screening in Hungary. Value in Health, 15(1), 39-45. doi:10.1016/j.jval.2011.10.003 Link

Walter, S., Mackenbach, J., Vokó, Z., Lhachimi, S., Ikram, M. A., Uitterlinden, A. G., Newman, A. B., Murabito, J. M., Garcia, M. E., Gudnason, V., Tanaka, T., Tranah, G. J., Wallaschofski, H., Kocher, T., Launer, L. J., Franceschini, N., Schipper, M., Hofman, A., & Tiemeier, H. (2012). Genetic, Physiological, and Lifestyle Predictors of Mortality in the General Population. American Journal of Public Health, 102(4), e3-e10. doi:10.2105/ajph.2011.300596 Link

2011

Agh, T., Inotai, A., & Meszaros, A. (2011). Factors Associated with Medication Adherence in Patients with Chronic Obstructive Pulmonary Disease. Respiration, 82(4), 328-334. doi:10.1159/000324453 Link

Gorog, K., Pattenden, S., Antova, T., Niciu, E., Rudnai, P., Scholtens, S., Splichalova, A., Slotova, K., Vokó, Z., Zlotkowska, R., & Houthuijs, D. (2011). Maternal smoking during pregnancy and childhood obesity: results from the CESAR Study. Matern Child Health J, 15(7), 985-992. doi:10.1007/s10995-009-0543-5 Link

Inotai, A., Rojkovich, B., Fülöp, A., Jászay, E., Ágh, T., & Mészáros, Á. (2011). Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatology International, 32(4), 963-969. doi:10.1007/s00296-010-1721-x Link

Kaló, Z., & Vokó, Z. (2011). Health technology assessment: a European collaboration. Expert Review of Pharmacoeconomics & Outcomes Research, 11(1), 41-43. doi:10.1586/erp.10.90 Link

Losonczy, G., Fekete, Á., Vokó, Z., Takács, L., Káldi, I., Ajzner, É., Kasza, M., Vajas, A., Berta, A., & Balogh, I. (2011). Analysis of complement factor H Y402H, LOC387715, HTRA1 polymorphisms and ApoE alleles with susceptibility to age-related macular degeneration in Hungarian patients. Acta Ophthalmologica, 89(3), 255-262. doi:10.1111/j.1755-3768.2009.01687.x Link

Nagy, B., Brennan, A., Brandtmüller, A., Thomas, S. K., Sullivan, S. D., & Akehurst, R. (2011). Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry, 26(5), 483-494. doi:10.1002/gps.2551 Link

Nagy, B., Nagyjanosi, L., Nagyistok, S., Józwiak-Hagymásy, J., Dessewffy, Z., Kalo, Z., & Vokó, Z. (2011). PDB82 Development of a Health Economic Model to Compare the Prevention, Treatment and Management Strategies of Type 2 Diabetes. Value in Health, 14(7), A486-A487. doi:10.1016/j.jval.2011.08.1385 Link

Nagyjanosi, L., Martos, É., Bödönyi, D., & Vokó, Z. (2011). PCV67 Health-Economic Impact of the Hungarian Salt Intake Reduction Program. Value in Health, 14(7), A376. doi:10.1016/j.jval.2011.08.787 Link

Ohmann, C., Kuchinke, W., Canham, S., Lauritsen, J., Salas, N., Schade-Brittinger, C., Wittenberg, M., McPherson, G., McCourt, J., Gueyffier, F., Lorimer, A., & Torres, F. (2011). Standard requirements for GCP-compliant data management in multinational clinical trials. Trials, 12(1). doi:10.1186/1745-6215-12-85 Link

Papp, K., Végh, P., Hóbor, R., Szittner, Z., Vokó, Z., Podani, J., Korányi, K. L., Czirják, L. K., & Prechl, J. (2011). Functional serum antibody profiles in autoimmune disease diagnostics. Molecular Immunology, 48(14), 1732. doi:10.1016/j.molimm.2011.06.432 Link

Petrovski, B. É., Széles, G., Melles, M., Pataki, V., Kardos, L., Jenei, T., Ádány, R., & Vokó, Z. (2011). Behaviour does not fully explain the high risk of chronic liver disease in less educated men in Hungary. European Journal of Public Health, 21(5), 662-666. doi:10.1093/eurpub/ckq079 Link

Szabo RP, Asztalos L, Szabo L, Balla J, Voko Z: Validation of a prognostic function for renal transplant recipients in Hungary JOURNAL OF NEPHROLOGY 24:(5) pp. 619-624. (2011) Link

Vokó, Z., de Brouwer, S., Lubsen, J., Danchin, N., Otterstad, J.-E., Dunselman, P. H. J. M., & Kirwan, B.-A. (2011). Long-term impact of secondary preventive treatments in patients with stable angina. European Journal of Epidemiology, 26(5), 375-383. doi:10.1007/s10654-011-9558-5 Link

2010

Ágh, T., & Mészáros, Á. (2010). Compliance and persistence with medications for chronic obstructive pulmonary disease. Clinical and Experimental Medical Journal, 4(1), 15-22. doi:10.1556/cemed.4.2010.28691 Link

Bodrogi, J., & Kaló, Z. (2010). Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. British Journal of Pharmacology, 159(7), 1367-1373. doi:10.1111/j.1476-5381.2009.00550.x Link

Inotai, A., Hankó, B., & Mészáros, Á. (2010). Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. Pharmacoepidemiology and Drug Safety, 19(2), 183-190. doi:10.1002/pds.1893 Link

Kalo, Z., Kiss, Z., Gerendy, P., Nagyjanosi, L., & Voko, Z. (2010). COST OF RENAL REPLACEMENT THERAPY IN HUNGARY. Transplantation Journal, 90, 735. doi:10.1097/00007890-201007272-01416 Link

Kuchinke, W., Ohmann, C., Yang, Q., Salas, N., Lauritsen, J., Gueyffier, F., Leizorovicz, A., Schade-Brittinger, C., Wittenberg, M., Voko, Z., Gaynor, S., Cooney, M., Doran, P., Maggioni, A., Lorimer, A., Torres, F., McPherson, G., Charwill, J., Hellström, M., & Lejeune, S. (2010). Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. Trials, 11(1). doi:10.1186/1745-6215-11-79 Link

Vokó, Z., Danchin, N., de Brouwer, S., Kirwan, B.-A., Poole-Wilson, P. A., & Lubsen, J. (2010). Correlates of coronary angiography in patients with stable angina and geographical differences in its utilisation: The ACTION experience. International Journal of Cardiology, 138(1), 56-62. doi:10.1016/j.ijcard.2008.08.036 Link

Voko Z, Nagyjanosi L, Kalo Z. Cost-effectiveness analysis of adding hpv vaccination to cervical cancer screening program in hungary. VALUE IN HEALTH 13:(7) pp. A270-A271. (2010) Link

2009

Inotai, A., & Mészáros, Á. (2009). Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis. International Journal of Technology Assessment in Health Care, 25(02), 190-195. doi:10.1017/s0266462309090242 Link

Voko, Z., Csepe, P., Nemeth, R., Kosa, K., Kosa, Z., Szeles, G., & Adany, R. (2009). Does socioeconomic status fully mediate the effect of ethnicity on the health of Roma people in Hungary? Journal of Epidemiology & Community Health, 63(6), 455-460. doi:10.1136/jech.2008.079715 Link

2008

Bhalla, A., Grieve, R., Rudd, A. G., & Wolfe, C. D. A. (2008). Stroke in the Young: Access to Care and Outcome; A Western Versus Eastern European Perspective. Journal of Stroke and Cerebrovascular Diseases, 17(6), 360-365. doi:10.1016/j.jstrokecerebrovasdis.2008.04.002 Link

Nagy, B., & Brandtmüller, Á. (2008). Implementing Risk Adjusted Capitation Payments with Health Care Reforms in Hungary. Competitio, 7(2), 147-160. doi:10.21845/comp/2008/2/8 Link

Takemoto, S. K., Arns, W., Bunnapradist, S., Garrison, L. P., Guirado, L., Kalo, Z., Oniscu, G., Opelz, G., Scolari, M. P., Stefoni, S., Yaqoob, M., & Brennan, D. C. (2008). Expanding the Evidence Base in Transplantation: The Complementary Roles of Randomized Controlled Trials and Outcomes Research. Transplantation, 86(1), 18-25. doi:10.1097/tp.0b013e31817d4df5 Link

Publications in hungarian language

Agh T, Agh L: The significance of medication compliance and persistence in hypertension, diabetes mellitus and dyslipidaemia [in Hungarian]. MEDICUS UNIVERSALIS 42: 3-6. (2009)
Agh T, Bartfai Z, Meszaros A: Relation of adherence to quality of life in COPD patients. [in Hungarian]. MEDICINA THORACALIS 63: 197. (2010)
Agh T, Bodnar R, Agh L: The importance of quality of life monitoring in the management of asthma [in Hungarian]. MEDICUS UNIVERSALIS 43: 179-181. (2010)
Agh T, Meszaros A, Bartfai Z: Quality of life and adherence in chronic obstructive pulmonary disease [in Hungarian]. MEDICAONLINE
Agh T, Meszaros A: Compliance and persistence with medication in chronic obstructive pulmonary disease [in Hungarian]. ORVOSI HETILAP 150: 1497-1502. (2009)
Agh T, Meszaros A: Pharmacoeconomic impact of compliance [in Hungarian]. ACTA PHARMACEUTICA HUNGARICA 80: 75-80. (2010)
Antal J, Szepezdi Zs, Nagyjánosi L, Kaló Z. A nemzetközi klinikai vizsgálatok helyzete és hozadéka Magyarországon. IME, 2010. 10. 1. 5-10.
Bogos, K., Kiss, Z., Gálffy, G., Tamási, L., Ostoros, G., Müller, V., Urbán, L., Bittner, N., Sárosi, V., Vastag, A., Polányi, Z., Nagy-Erdei, Z., Vokó, Z., Nagy, B., Rokszin, G., Abonyi-Tóth, Z., & Moldvay, J. (2020). [Novel approaches to the epidemiology of lung cancer in Hungary]. Magy Onkol, 64(3), 175-181.
Bartfai Z, Agh T, Domotor P, Bartfai L, Meszaros A. Therapeutic opportunities derived from clinical differences among inhaled corticosteroids. [in Hungarian] MEDICINA THORACALIS5:339-344. (2015)
Barkai L, Blatniczky L, Halmos T, Hidvégi T, Jermendy Gy, Kaló Z, Madácsy L, Vándorfi Gy, Winkler G, Wittmann I. Nemzeti Diabetesprogram. Diabetologia Hungarica, 2011. 19. 3. Supplementum 5-39.
Bendes R, Németh B, Pitter JG, Kóczián K, Götze Á, Kaló Z. Magyarországon becsült életminőséggel korrigált életévnyereség lehetősége a negatív tünetes szkizofréniában kariprazin alkalmazása esetén. LAM. 2019. 29(10). 467-475.
Inotai A, Csanadi M, Agh T. Real world data analysis to improve drug policy decision making in Central Eastern European countries. [in Hungarian] IME INTERDISZCIPLINARIS MAGYAR EGESZSEGUGY 15: 47-52. (2016)
Inotai A, Kalo Z Meszaros A: Decision analytic modeling and their impact on health care decision making. [in Hungarian] ACTA PHARM HUNG 79: 63-69. (2009)
Inotai A, Kalo Z: Risk sharing methods in middle income countries [in Hungarian]. ACTA PHARM HUNG 82: 43-52. (2012)
Inotai A, Kalo Z: The assessment of innovation and the R&D&I strategy of public health care sector [in Hungarian]. EGESZSEGUGYI GAZDASAGI SZEMLE 48: 33-38. (2010)
Inotai A, Merész G, Csetneki K, Kaló Z. A gyógyszerkiadások nemzetközi összehasonlításának módszertani kérdései és ezek hatásai a magyarországi kormányzati intézkedésekre. IME. 2015. 14. 8. 55-60.
Inotai A, Meresz G, Kalo Z: Assessment of Hungarian pharmaceutical expenditures with respect to Szell Kalman Plan [in Hungarian]. EGESZSEGUGYI GAZDASAGI SZEMLE 49: 9-13. (2011)
Inotai A, Meresz G, Kalo Z: Assessment of the pharmaceutical expenditure in Hungary [in Hugarian]. ACTA PHARM HUNG 80: 162-172. (2010)
Inotai A, Meszaros A: Cost effectiveness of celecoxib in rheumatoid arthritis [in Hungarian], IME 7: 48-50. (2008)
Inotai A, Nagy B, Kalo Z: Biosimilars and evidence based decision making in Central Eastern European countries. [in Hungarian] ORVOSTOVABBKEPZO SZEMLE 19: 69-73. (2012)
Inotai A, Rojkovich B, Meszaros A: The assessment of oral NSAID use in patients with rheumatoid arthritis in Hungary-a cross sectional non interventional study. [in Hungarian] ACTA PHARM HUNG 80: 47-54. (2010)
Inotai A, Vincze Z: Cost study of NSAID use in rheumatoid arthritis based on recent therapeutic protocols [in Hungarian], ACTA PHARM HUNG 78: 79-86. (2008)
Jozwiak-Hagymasy J, Voko Z: Use of inhalation devices in asthma and chronic obstructive pulmonary disease: a Delphi consensus panel [in Hungarian] IME 14:1 48:53. (2015)
Kaló Z. Az egészség-gazdaságtani elemzések és az objektív támogatáspolitikai rendszer dilemmái Magyarországon, LAM, 2009. 19. 4–5. 329–333.
Kalo Z, Boncz I, Dank M, Koczian K, Molnar MJ, Nagy B, Nemeth Gy, Pitter J, Zelei T. Health Economic Aspects of Personalized Medicine: Do Personalized Technologies Reduce Health Expenditure? [in Hungarian] IME13. 5. 41-45. (2014)
Kalo Z, Meresz G, Mezei D, Totth A, Inotai A: The grounding and implications of Szell Kalman Plan [in Hungarian]. IME AZ EGESZSEGUGYI VEZETOK SZAKLAPJA 11:6 12-16. (2012)
Kalo Z, Nagy B: Methodological questions in assessing the cost effectiveness of prevention programs. [in Hungarian] EGESZSEGUGYI GAZDASAGI SZEMLE 50:1 29-31. (2012)
Kaló Z, Jermendy Gy, Winkler G, Hidvégi T, Borsi A, Novákné Pékli M, Kincses J, Kalotai Z, Vokó Z: A cukorbetegség társadalmi terhe és egészségügyi prioritásának indoka. Diabetologia Hungarica, 2011. 19. 3. 245–251.
Kaló Z, Nagy B. Paradigmaváltás a preventív egészségügyi befektetések gazdasági megítélésében – Hogyan mérjük egy védőoltás költséghatékonyságát? IME, 2008. 7. 8. 42-45.
Kaló Z, Bors K, Dank M, Géczi L, Horváth Cs, Jermendy Gy, Kalotai Z, Kincses J, Margitai B, Novákné Pékli M, Vasvári A, Thurzó L, Vokó Z, Winkler G, Zalatnainé Tóth K. Együtt az egészségért: az életminőség mérésének jelentősége a bizonyítékokon alapuló egészségpolitikai döntéshozatalban, Orvostovábbképző Szemle. 2009. 16. 9. 12-14.
Kaló Z, Józwiak-Hagymásy J, Németh A. A napi adagolás, mint a beteg-együttműködést befolyásoló tényező –vizsgálata szkizofréniában szenvedő betegek körében IME, 2010. 9. 5. 37-42.
Kaló Z, Vokó Z: A kockázatmegosztás szerepe a gyógyszerek finanszírozásában. LAM 2010. 20. 3-4. 237-241.
Kaló Z, Kovács A, Margitai B, Mészner Zs, Vokó Z. „Value of vaccine – A védőoltás érték” program Fehér Könyve. IME, 2010. 10. 1. 39-44.
Marton I, Masszi T, Kaló Z. A Transzparencia Direktíva implementálásának kérdései a deferazirox ártámogatása kapcsán. IME, 2009. 8. 1. 40-44.
Meresz G, Kalo Z, Tabak A: Cost minimisation analysis of basal insulin analogues for treatment of type 2 diabetes. [in Hungarian] LEGE ARTIS MEDICINAE 22(12):669–676. (2012)
Meresz G., Foldesi Cs., Nagyistok Sz., Vincziczki A.: Changes on the market of publications and a dynamising health economic researcher community [in Hungarian]. EGESZSEGUGYI GAZDASAGI SZEMLE 2014/2-3, p36-41.
Meszaros A, Agh T, Bartfai Z, Orosz M: Quality of life decrement and health burden in asthma and COPD [in Hungarian]. MEDICINA THORACALIS 65: 219. (2012)
Meszaros A, Szabo L, Agh T, Fujsz E, Bartfai Z: Measurement of health related quality of life and asthma control in Hungary [in Hungarian]. TUDOGYOGYASZAT 5: 28-31. (2011)
Nagy B, Brandtmuller A, Dozsa Cs: The Redistributive Role of the State in the British and Dutch Health Care Market. Is there another Way? [in Hungarian] TARSADALOMKUTATAS (SOCIAL SCIENCE RESEARCH) 27: 2117-2138. (2009)
Nagy B, Brennan A, Skultety L, Nagy J, Szentesi A, Dessewffy Z, Kalotai Z: The cost effectiveness of rivastigmine transdermal patch in the management of patients with mild and moderate Alzheimer’s disease [in Hungarian]. IME 8:3 40-45. (2009)
Nagy B, Meresz G: Role of risk-sharing in health care. [in Hungarian] EGESZSEGUGYI GAZDASAGI SZEMLE November 1; 50(4): 42-48. (2012)
Nagy B, Nagyjanosi L, Nagyistok Sz, Jozwiak-Hagymasy J, Meresz G, Papp E, Dessewffy Z, Jermendy GY, Winkler G, Kalo Z, Voko Z: Health economic modell to assess the screening, treatment and management strategies of diabetes. [in Hungarian] DIABETOLOGIA HUNGARICA 20.4 p.245-255. (2012)
Nagy B, Rakonczai P, Gulacsi L: Application of statistical methods to calculate capitation payments in the Hungarian health care. [in Hungarian] STATISZTIKAI SZEMLE (HUNGARIAN STATISTICAL REVIEW) 86:4 321-341. (2008)
Nagy B, Rakonczai P, Sipos J: Predicting health care expenditures with demographic characteristics for designing capitation payments in Hungary [in Hungarian]. IME 7:Egeszseg-gazdasagtani kulonszam 5-9. (2008)
Nagy B, Kaló Z, Hegyi R. Paradigmaváltás a preventív egészségügyi befektetések gazdasági megítélésében III. IME, 2008. 7. 10. 24-29.
Nagy B, Kaló Z: Paradigmaváltás a preventív egészségügyi befektetések gazdasági megítélésében - Egészséges társadalom és gazdasági növekedés: ok és okozat? IME, 2008. 7. 7. 37-40.
Nagy B: Resource allocation in Hungarian health care - Is there a missing link? [in Hungarian]. KOZGAZDASAGI SZEMLE 57:4 337-353. (2010)
Nemeth B. [Possibility of Quality-adjusted Life Year Gain with Cariprazine in Patients with Negative Symptoms of Schizophrenia in Hungary] LAM (Lege Artis Medicinæ) - 2019;29(08-09):389–394.
Nemeth B. Health Economics in Hungary: Great potential, missed opportunity? [in Hungarian] LAM (LEGE ARTIS MEDICINÆ) 28(06-07). (2018)
Németh J, Nagyjánosi L, Nagyistók Sz, Tolnayné Csattos M, Szabóné Berta I, Kincse É, Szulyák E, Boér I, Hundzsa Gy, Kaló Z, Berta A. Időskori vakság betegségterhe Magyarországon; LAM 2011. 21. 10. 641–647.
Orosz E, Meresz G, Nagy B: Investment to human capital: fallback from the developed countries? [in Hungarian] EDUCATIO. Volume 22, Number 2, 2013., p159-176.
Orosz M, Galffy G, Agh T, Kovacs D, Meszaros A: The everyday life of patients with asthma or COPD. [in Hungarian]. MEDICINA THORACALIS 63: 181-182. (2010)
Rojkovich B, Inotai A: Cardiovascular safety of nonsteroidal antiinflammatory drugs [in Hungarian]. LEGE ARTIS MEDICINAE 21: 123-125. (2011)
Voko Z, Barra M, Molnar A, Kerpel-Fronius A, Bajzik G, Horvath I, Moizs M, Nagy B. Model concept of the health economic evaluation of low-dose CT lung cancer screening in Hungary. [in Hungarian] ORVOSI HETILAP 158.25. pp. 963–975. (2017)
Voko Z, Turi G, Zsolyom A. Cost-effectiveness of oral cancer screening in Hungary. [in Hungarian] ORVOSI HETILAP 157(29), 1161–1170. (2016)
Voko Z, Zsolyom A, Jermendy Gy. Diabetes attributable mortality in Hungary in 2000-2009.[in Hungarian] LEGE ARTIS MEDICINAE 26:265-270. (2016)
Voko Z, Inotai A, Horvath Cs, Bors K, Speer G, Kalo Z: Quality of Life of Patients With Osteoporosis In Hungary. [in Hungarian] LAM KID 3(4). (2013)
Voko Z, Nagyjanosi L, Kalo Z: Direct health care costs of diabetes mellitus in Hungary [in Hungarian], LEGE ARTIS MEDICIANE 19(12):775-780. (2009)
Vokó Z, Kaló Z: Prevenció - kiadások – hatékonyság, Egészségügyi Gazdasági Szemle, 2012. 50. 1. 6-8.
Zemplenyi AT, Mangel L, Kalo Z, Endrei D, Lohner S, Boncz I. Meta-analysis of the side-effect profiles of modern radiation therapies for patients with prostate cancer (Article in Hungarian). ORVOSI HETILAP 157(20):776-88. (2016)
Zemplenyi AT, Mangel L, Kalo Z, Endrei D, Boncz I. A microcosting study of radiation therapy of localized prostate cancer. (in Hungarian) ORVOSI HETILAP 157. 12. 461-8. (2016)

Scientific publications

2020

TODAY'S RESEARCH FOR TOMORROW'S HEALTH